Apomorphine Articles
Ipsen sells North American rights for Apokyn to Britannia Pharma
3 November 2011
Archimedes reports strong data for IN drugs
2 March 2009
Ipsen's revenues up 6% on new US launches
9 February 2009
Ipsen finalizes purchase of Vernalis
7 July 2008
Vernalis FY 2007 income reaches $39.5M
5 May 2008
Stock Commentary - Europe - week to Feb 25, 2008
3 March 2008
Vernalis announces staff cuts and restructuring
25 February 2008
Vectura's inhaled PD drug impresses at Ph II
12 November 2007
Vernalis' 6-month loss narrows 29%, on sales
24 September 2007
Vectura's ED drug impresses in 2nd Ph IIb study
30 April 2007
Vernalis' 2006 loss up 29% on Apokyn costs
19 March 2007
Amarin's loss deepens 12% on R&D costs
19 February 2007
Vernalis recruits Jean Hubble for US post
22 January 2007
Vernalis' losses for 1st-half 2006 down slightly
18 September 2006
Stock Commentary - Europe - week to Sept 4, 2006
11 September 2006
Vectura's PD drug successful in Ph II study
14 August 2006
Mylan sees record 1st-qtr 2007 revenues
7 August 2006
Amarin acquires novel oral apomorphine
29 May 2006
Vernalis' 2005 losses rise to L32.8M
27 March 2006
Mylan sees solid third-quarter results
13 February 2006
Vectura's loss per share drops 33% to 8.6 pence
4 July 2005
Britannia introduces new pre-filled syringe
17 January 2005
Mylan changes name of branded prods unit
21 June 2004
Bartek's Apokyn cleared by FDA
24 May 2004
Positive results for Vecura's VRoo4 in ED
28 July 2003
Mylan's apomorphine on track for approval
21 July 2003
Pfizer merger oked by EC but not without cost
10 March 2003
Pfizer/Pharmacia merger clears EU hurdle
3 March 2003
Pharmacia, Pfizer merger provides ED windfall for Nastech
3 February 2003
Britannia plans nasal drug for impotence
10 June 2002
Pharmacia pays Nastech $2M milestone payment
10 June 2002
Review of eplerenone gets underway in USA
11 February 2002
Chiesi of Italy sets out expansion plans for rest of Europe
29 November 2001
Nastech Pharma placement raises $5.8 million
22 October 2001
Nastech says intranasal delivery can target brain
18 July 2001
Stock Commentary - Tokyo
28 June 2001
Japan pharma stock market, week to June 25
27 June 2001
Nastech initiates Ph II FSD trials
15 June 2001
CPMP backs first oral ED drug, apomorphine
26 January 2001
Overseas sales boost Orion Pharma
10 November 2000
Nastech sees positive Ph I data in FSD
12 October 2000
Stock Commentary Tokyo
6 July 2000
Bayer sees potential in Viagra rival
2 June 2000
Stock Commentary Tokyo
27 April 2000
Stock Commentary Tokyo
19 April 2000
Stock Commentary Tokyo
13 April 2000
Nastech's intranasal apomorhpine, more effective than Viagra?
24 February 2000
Stock Commentary Tokyo
27 January 2000
Nastech files NDA for intranasal scopolamine
21 December 1999
Abbott seeks European license for Uprima
16 December 1999
HSBC explores Uprima potential for ED
20 August 1999
Zonagen crashes as FDA terminates phentolamine studies
12 August 1999
Nastech plans intranasal trials of apomorphine
22 July 1999
Stock Commentary Tokyo
8 July 1999
TAP files for Viagra competitor in USA
2 July 1999
Drug development news in brief
10 March 1999
Takeda entering new phase of global expansion, says MSDW analyst
18 February 1999
Britannia up for sale
19 January 1999
Stock Commentary Tokyo
10 December 1998
Takeda Entering New Product Cycle
21 September 1998
Takeda Pharma Sets Up Swiss Subsidiary
11 September 1998
Chiesi Aims For Top 20 Place In Italian Market
5 August 1998
Viagra Still Riding High, But Competition Looms
15 June 1998
Synthelabo Reports On New Products
17 April 1995
NEW APPROACHES IN TREATING PARKINSONISM
7 December 1992
Showing 1-82 of 82 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
